Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
14 nov. 2024 16h30 HE
|
Exagen Inc.
CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the validation and regulatory submission for approval of new Systemic Lupus...
Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024
14 nov. 2024 16h05 HE
|
Alumis Inc.
Data at ACR for ESK-001, oral TYK2 inhibitor, demonstrates potential as a high efficacy oral for treatment of Systemic Lupus Erythematosus (SLE).
Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements
13 nov. 2024 16h05 HE
|
Alumis Inc.
Alumis reports third quarter 2024 financial results, highlights positive data and near term milestones for its ongoing clinical programs.
Medicovestor, Inc. Announces Issuance/Approval of 3 Patents by the USPTO
28 oct. 2024 10h00 HE
|
Medicovestor Inc
Medicovestor secures 3 USPTO patents, advancing its innovative ADC platform and unique antibodies for enhanced cancer treatment and autoimmune potential.
Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study
27 sept. 2024 09h00 HE
|
Alumis Inc.
Late breaking research presentation at EADV shows increasing and sustained responses in 28-week Phase 2 data for ESK-001 in psoriasis
U.S. IVD And LDT For Autoimmune Diseases Market Research 2024-2030: Rising Awareness of Autoimmune Disorders Fuels Demand for Innovative Diagnostic Solutions
24 sept. 2024 10h29 HE
|
Research and Markets
Dublin, Sept. 24, 2024 (GLOBE NEWSWIRE) -- The "U.S. IVD And LDT For Autoimmune Diseases Market Size, Share & Trends Analysis Report By Type (IVD, LDT), By Technology (Immunoassays, Clinical...
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
29 août 2024 16h05 HE
|
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Apheresis Market Size to Surge to USD 6.7 Billion by 2034, Driven by Strong Growth Momentum at 7.7% CAGR | Report by Transparency Market Research, Inc.
28 août 2024 18h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research, Inc. , Aug. 28, 2024 (GLOBE NEWSWIRE) -- As per the report published by Transparency Market Research, the global apheresis market...
ImmuneSensor Therapeutics Receives Clearance from Australian Regulators to Initiate a First-in-Human Phase 1 Clinical Trial of cGAS inhibitor Drug Candidate, IMSB301
19 août 2024 08h00 HE
|
ImmuneSensor Therapeutics
Novel, oral IMSB301 is a potent cGAS inhibitor designed to block signaling through a central pathway that drives diverse inflammatory and autoimmune diseases Company expects to initiate its Phase 1...
Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
08 août 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics Reports Second Quarter 2024 Financial Results
and Business Updates